Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 1;108(11):2174-2185.
doi: 10.1097/TP.0000000000005025. Epub 2024 Apr 8.

Nanoparticle-assisted Targeting Delivery Technologies for Preventing Organ Rejection

Fanchao Meng  1   2 , Yang Fu  3 , Haiyang Xie  2 , Hangxiang Wang  1   2
Affiliations
Review

Nanoparticle-assisted Targeting Delivery Technologies for Preventing Organ Rejection

Fanchao Meng et al. Transplantation. .

Abstract

Although organ transplantation is a life-saving medical procedure, the challenge of posttransplant rejection necessitates safe and effective immune modulation strategies. Nanodelivery approaches may have the potential to overcome the limitations of small-molecule immunosuppressive drugs, achieving efficacious treatment options for transplant tolerance without compromising overall host immunity. This review highlights recent advances in biomaterial-assisted formulations and technologies for targeted nanodrug delivery with transplant organ- or immune cell-level precision for treating graft rejection after transplantation. We provide an overview of the mechanism of transplantation rejection, current clinically approved immunosuppressive drugs, and their relevant limitations. Finally, we discuss the targeting principles and advantages of organ- and immune cell-specific delivery technologies. The development of biomaterial-assisted novel therapeutic strategies holds considerable promise for treating organ rejection and clinical translation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Barker CF, Markmann JF. Historical overview of transplantation. Cold Spring Harb Perspect Med. 2013;3:a014977.
    1. Black CK, Termanini KM, Aguirre O, et al. Solid organ transplantation in the 21(st) century. Ann Transl Med. 2018;6:409.
    1. Colombo D, Ammirati E. Cyclosporine in transplantation—a history of converging timelines. J Biol Regul Homeost Agents. 2011;25:493–504.
    1. Adam R, Karam V, Cailliez V, et al.; All Contributing Centers ( www.eltr.org ) and the European Liver and Intestine Transplant Association (ELITA). Improved survival in liver transplant patients receiving prolonged-release tacrolimus-based immunosuppression in the European Liver Transplant Registry (ELTR): an extension study. Transplantation. 2019;103:1844–1862.
    1. Lai Q, Iesari S, Finkenstedt A, et al. Hepatocellular carcinoma recurrence after acute liver allograft rejection treatment: a multicenter European experience. Hepatobiliary Pancreat Dis Int. 2019;18:517–524.

Publication types

MeSH terms

Substances

LinkOut - more resources